Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 5/2024

01-05-2024 | Gynecologic Cancer | Review Article

Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review

Authors: Sandipan Dasgupta, Sakuntala Gayen, Tania Chakraborty, Naureen Afrose, Ranita Pal, Sutapa Mahata, Vilas Nasare, Souvik Roy

Published in: Medical Oncology | Issue 5/2024

Login to get access

Abstract

Gynecological malignancies are most leading causes of death among women worldwide. The high prevalence of gynecologic malignancies remains significant, necessitating to turn the novel treatment approach like immunotherapy, wherein cancer cells are killed by the invasion of immune system. In recent year, immunotherapy has mostly an advanced treatment approach to repressing the tumor cells survival, proliferation, and invasion via the activation of immune systems. Moreover, various types of immune cells including T-cells, B-cells, and dendritic cells are associated with the immunotherapeutic strategy in cancer treatment. Although the significant role of T-cells against cancer is well established, while B-cells and dendritic cells also play an important role against different gynecological cancer by regulating the immune system. This review focuses on that arena and highlight the role of immune cells in the treatment of gynaecological cancer. Various immune cell-based anticancer therapies such as T-cell therapies, Adoptive Cellular transfer, B-cell therapies as well as approaches to Dendritic Cell therapies have been discussed in detail. Furthermore, the clinical settings and future avenues regarding immunotherapy on gynecological cancer have also been reviewed and illuminated in the recent study.
Literature
1.
Decker WK, da Silva RF, Sanabria MH, Angelo LS, Guimarães F, Burt BM, et al. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. 2017;8:829.PubMedPubMedCentralCrossRef
2.
Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat. 2017;3:250–61.CrossRef
3.
Halliday GM, Patel A, Hunt MJ, Tefany FJ, Barnetson RS. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg. 1995;19:352–8.PubMedCrossRef
4.
5.
Nikanjam M, Mullen J, Yacoub C, Daniels GA. Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series. J Med Case Rep. 2022;16(1):337.PubMedPubMedCentralCrossRef
6.
Lynam S, Lugade AA, Odunsi K. Immunotherapy for gynecologic cancer: current applications and future directions. Clin Obstet Gynecol. 2020;63(1):48–63.PubMedPubMedCentralCrossRef
7.
Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011;241(1):104–18.PubMedPubMedCentralCrossRef
8.
9.
Nishio H, Iwata T, Aoki D. Current status of cancer immunotherapy for gynecologic malignancies. Jpn J Clin Oncol. 2021;51(2):167–72.PubMedCrossRef
10.
Lorusso D, Ceni V, Daniele G, Pietragalla A, Salutari V, Muratore M, et al. Immunotherapy in gynecological cancers. Explor Target Antitumor Ther. 2021;2(1):48–64.PubMedPubMedCentral
11.
Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, et al. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. Cancer Treat Rev. 2017;59:109–16.PubMedCrossRef
12.
Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH. Molecular signatures mostly associated with NK cells arepredictive of relapse free survival in breast cancer patients. J Transl Med. 2013;11(1):145.PubMedPubMedCentralCrossRef
13.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells withinhuman colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.PubMedCrossRef
14.
Ginsburgs VH, Goodill SW. A dance/movement therapy clinical model for women with gynecologic cancer undergoing high dose rate brachytherapy. Am J Dance Ther. 2009;31(2):136–58.CrossRef
15.
Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–84.PubMedPubMedCentralCrossRef
16.
17.
18.
19.
Lanza R, Russell DW, Nagy A. Engineering universal cells that evade immune detection. Nat Rev Immunol. 2019;19(12):723–33.PubMedCrossRef
20.
Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16(10):599–611.PubMedCrossRef
21.
Donadon M, Hudspeth K, Cimino M, Di Tommaso L, Preti M, Tentorio P, et al. Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival. J Gastrointest Surg. 2017;21(8):1226–36.PubMedCrossRef
22.
23.
van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naive T cells. Nat Rev Immunol. 2018;18(6):363–73.PubMedCrossRef
24.
25.
Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol. 2004;4:123–32.PubMedCrossRef
26.
Wilson IA, Garcia KC. T-cell receptor structure and TCR complexes. Curr Opin Struct Biol. 1997;7:839–48.PubMedCrossRef
27.
Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445–80.PubMedCrossRef
28.
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68.PubMedPubMedCentralCrossRef
29.
Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood. 2018;131(3):311–22.PubMedPubMedCentralCrossRef
30.
31.
Chen Z, Zhu Y, Du R, Pang N, Zhang F, Dong D, et al. Role of regulatory B cells in the progression of cervical cancer. Mediat Inflamm. 2019;2019:1–8.
32.
33.
34.
35.
Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27− memory phenotype and together with CD8+ T-cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18(12):3281–92.PubMedCrossRef
36.
37.
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24.PubMedCrossRef
38.
Wylie B, Macri C, Mintern JD, Waithman J. Dendritic cells and cancer: from biology to therapeutic intervention. Cancers (Basel). 2019;11(4):521.PubMedCrossRef
39.
Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci. 1990;87(19):7698–702.PubMedPubMedCentralCrossRef
40.
Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257–67.PubMedCrossRef
41.
42.
Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–82.PubMedCrossRef
43.
44.
Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7–1 and B7–2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004;21(3):401–13.PubMedCrossRef
45.
Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–60.PubMedPubMedCentralCrossRef
46.
Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.PubMedPubMedCentralCrossRef
47.
Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100(8):4712–7.PubMedPubMedCentralCrossRef
48.
Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018;6(1):35.PubMedPubMedCentralCrossRef
49.
Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020;157(1):161–6.PubMedPubMedCentralCrossRef
50.
Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981.PubMedPubMedCentralCrossRef
51.
Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med. 2013;11(1):1–11.CrossRef
52.
Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Zhao X, et al. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J Exp Clin Cancer Res. 2021;40(1):1–16.CrossRef
53.
Smith M, Lara OD, O’Cearbhaill R, Knisely A, McEachron J, Gabor L, et al. Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection. Gynecol Oncol. 2020;159(3):618–22.PubMedPubMedCentralCrossRef
54.
Li J, Cao C, Xiang Y, Hong Z, He D, Zhong H, et al. TLT2 suppresses Th1 response by promoting IL-6 production in monocyte through JAK/STAT3 signal pathway in tuberculosis. Front Immunol. 2020;11:2031.PubMedPubMedCentralCrossRef
55.
56.
Anderson K, Eskander RN. Immune checkpoint inhibition in the treatment of gynecologic cancer. Curr Obstet Gynecol Rep. 2018;7(1):6–19.CrossRef
57.
Barani M, Bilal M, Sabir F, Rahdar A, Kyzas GZ. Nanotechnology in ovarian cancer: diagnosis and treatment. Life Sci. 2021;266: 118914.PubMedCrossRef
58.
Bojadzic D, Chen J, Alcazar O, Buchwald P. Design, synthesis, and evaluation of novel immunomodulatory small molecules targeting the CD40–CD154 costimulatory protein-protein interaction. Molecules. 2018;23(5):1153.PubMedPubMedCentralCrossRef
59.
60.
Solinas C, Migliori E, De Silva P, Willard-Gallo K. LAG3: the biological processes that motivate targeting this immune checkpoint molecule in human cancer. Cancers. 2019;11(8):1213.PubMedPubMedCentralCrossRef
61.
Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3(12): e173290.PubMedPubMedCentralCrossRef
62.
Son J, George GC, Nardo M, Krause KJ, Jazaeri AA, Biter AB, et al. Adoptive cell therapy in gynaecologic cancers: a systematic review and meta-analysis. Gynecol Oncol. 2022;165(3):664–70.PubMedPubMedCentralCrossRef
63.
Wu JWY, Dand S, Doig L, Papenfuss AT, Scott CL, Ho G, et al. T-Cell receptor therapy in the treatment of ovarian cancer: a mini review. Front Immunol. 2021;12: 672502.PubMedPubMedCentralCrossRef
64.
Zhu Y, Zhou J, Zhu L, Hu W, Liu B, Xie L. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Hum Vaccin Immunother. 2022;18:5.CrossRef
65.
66.
Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124(11):1759–76.PubMedPubMedCentralCrossRef
67.
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319(25):1676–80.PubMedCrossRef
68.
Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango? Front Immunol. 2022;13:1018962.PubMedPubMedCentralCrossRef
69.
Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS ONE. 2009;4(3): e4749.PubMedPubMedCentralCrossRef
70.
Shafer P, Kelly LM, Hoyos V. Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects. Front Immunol. 2022;13: 835762.PubMedPubMedCentralCrossRef
71.
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233.PubMedPubMedCentralCrossRef
72.
Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. Bethesda, MD National Cancer Institute Bethesda, MD; 2019.
73.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.PubMedCrossRef
74.
Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol. 2008;180(1):72–8.PubMedCrossRef
75.
Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z. Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res. 2019;9(10):2064–78.PubMedPubMedCentral
76.
Serritella AV, Saenz-Lopez P, Dhar P, Liu S, Wu J. The clinical impact of soluble natural killer cell group 2-member D (NKG2D) receptor ligands on tumor tumorigenicity and anti-tumor immunity. J Clin Oncol. 2023;41(16):e14557.CrossRef
77.
Uppendahl LD, Dahl CM, Miller JS, Felices M, Geller MA. Natural killer cell-based immunotherapy in gynecologic malignancy: a review. Front Immunol. 2018;8:1825.PubMedPubMedCentralCrossRef
78.
Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Philip R, et al. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother (Hagerstown). 2012;35(2):196.CrossRef
79.
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 2010;107(17):7875–80.PubMedPubMedCentralCrossRef
80.
81.
De Jong R, Leffers N, Boezen H, ten Hoor KA, van der Zee AG, Hollema H, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114(1):105–10.PubMedCrossRef
82.
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positiveendometrial cancer: results from the KEYNOTE-028 study. J ClinOncol. 2017;35(22):2535–41.CrossRef
83.
Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–8.PubMedCrossRef
84.
Bonneville R, Krook MA, Chen HZ, Smith A, Samorodnitsky E, Wing MR, et al. Detection of microsatellite instability biomarkers via next-generation sequencing. Methods Mol Biol. 2020;2055:119–32.PubMedPubMedCentralCrossRef
85.
86.
87.
Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, et al. Lenvatinib plus pembrolizumabin patients with advanced endometrial cancer: an interim analysis of amulticentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–8.PubMedCrossRef
88.
Santin A, Hermonat P, Ravaggi A, Bellone S, Cowan C, Coke C, et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer. Gynecol Obstet Invest. 2000;49(3):194–203.PubMedCrossRef
89.
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777.PubMedPubMedCentralCrossRef
90.
Oaknin A, Duska L, Sullivan R, Pothuri B. Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer. Gynecol Oncol. 2019;154:17.CrossRef
91.
Doran SL, Stevanović S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, et al. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I/II study. J Clin Oncol. 2019;37(30):2759–68.PubMedPubMedCentralCrossRef
92.
Ge Y, Zhang Y, Zhao KN. Emerging therapeutic strategies of different immunotherapy approaches combined with PD-1/PD-L1 blockade in cervical cancer. Drug Des Devel Ther. 2022;16:3055–70.PubMedPubMedCentralCrossRef
93.
Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M. T-cell receptor repertoire sequencing and its applications: focus on infectious diseases and cancer. Int J Mol Sci. 2022;23(15):8590.PubMedPubMedCentralCrossRef
94.
Bryson P, Jia Q, Chen G, Li S, Fang J, Zhao L, et al. 1227p-HPV16 E6-SpecificTCR-T armored with checkpoint blockade in the treatment of cervical cancer. J Immunother Cancer. 2019;30: v502.
95.
Litwin TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, Stanley M, Wentzensen N. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. Br J Cancer. 2021;124(4):831–41.PubMedCrossRef
96.
Yu L, Lanqing G, Huang Z, Xin X, Minglin L, Fa-hui L, et al. T cell immunotherapy for cervical cancer: challenges and opportunities. Front Immunol. 2023;14:1105265.PubMedPubMedCentralCrossRef
97.
He Y, Li X, Yin C, Wu YM. Killing cervical cancer cells by specific ChimeriAntigen receptor-modified T cells. J Reprod Immunol. 2020;139: 103115.PubMedCrossRef
98.
Zhang Y, Li X, Zhang J, Mao L. Novel cellular immunotherapy UsingNKG2D CAR-T for the treatment of cervical cancer. Bio Med Pharmacother. 2020;131: 110562.CrossRef
99.
Xu Y, Jiang J, Wang Y, Wang W, Li H, Lai W, et al. Engineered T cell therapy for gynecologic malignancies: challenges and opportunities. Front Immunol. 2021;12: 725330.PubMedPubMedCentralCrossRef
100.
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncol. 2021;17:3781–5.PubMedCrossRef
101.
102.
Kerkar SP, Wang Z, Lasota J, Park T, Patel K, Groh E, et al. MAGE-A is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases. J Immunother. 2016;39:181–7.PubMedPubMedCentralCrossRef
103.
Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, et al. CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic malignancies. Mol Ther. 2020;28:548–60.PubMedCrossRef
104.
Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018;10(436):eaao5931.PubMedCrossRef
105.
Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res. 2013;19:4801.PubMedPubMedCentralCrossRef
106.
Fader AN, Diaz LA, Armstrong DK, Tanner EJ, Uram JN, Eyring A, et al. Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or persistent endometrial cancer. Gynaecol Oncol. 2016;141:206–7.CrossRef
107.
Yang C, Lee H, Jove V, Deng J, Zhang W, Liu X, et al. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS ONE. 2013;8(1): e54029.PubMedPubMedCentralCrossRef
108.
Wouters MC, Nelson BH. Prognostic significance of tumor-infiltrating B-cells and plasma cells in human cancer. Clin Cancer Res. 2018;24(24):6125–35.PubMedCrossRef
109.
Lundgren S, Berntsson J, Nodin B, Micke P, Jirström K. Prognostic impact of tumour-associated B-cells and plasma cells in epithelial ovarian cancer. J Ovarian Res. 2016;9(1):1–9.CrossRef
110.
111.
Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B cell chronic lymphocytic leukemia. Clin Cancer Res. 2005;11(19):6916–23.PubMedCrossRef
112.
Kugler A, Seseke F, Thelen P, Kallerhoff M, Müller GA, Stuhler G, et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br J Urol. 1998;82(4):487–93.PubMedCrossRef
113.
Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer. 2000;85(5):618–26.PubMedCrossRef
114.
115.
Dzopalic T, Rajkovic I, Dragicevic A, Colic M. The response of human dendritic cells to co-ligation of pattern-recognition receptors. Immunol Res. 2012;52:20–33.PubMedCrossRef
116.
Murthy V, Moiyadi A, Sawant R, Sarin R. Clinical considerations in developing dendritic cell vaccine-based immunotherapy protocols in cancer. Curr Mol Med. 2009;9:725–31.PubMedCrossRef
117.
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96:3102–8.PubMedCrossRef
118.
Bhargava A, Srivastava RK, Mishra DK, Tiwari RR, Sharma RS, Mishra PK. Dendritic cell engineering for selective targeting of female reproductive tract cancers. Indian J Med Res. 2018;148(Suppl):S50–63.PubMedPubMedCentral
119.
Chen B, Liu L, Xu H, Yang Y, Zhang L, Zhang F. Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer. Exp Ther Med. 2015;9:1063–7.PubMedPubMedCentralCrossRef
120.
Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, et al. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res. 2013;33:3855–9.PubMed
121.
Gray H, Benigno B, Berek J, Chang J, Mason J, Mileshkin L, et al. Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. J Immunother Cancer. 2016;4(1):34.PubMedPubMedCentralCrossRef
122.
Jiang L, Liu G, Ni W, Zhang N, Jie J, Xie F, et al. The combination of MBP and BCG-induced dendritic cell maturation through TLR2/TLR4 promotes Th1 activation in vitro and vivo. Mediat Inflamm. 2017;2017:1–14.
123.
Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563–604.PubMedCrossRef
124.
125.
126.
Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci. 2011;108(6):2384–9.PubMedPubMedCentralCrossRef
127.
Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II–restricted antigen presentation. Blood J Am Soc Hematol. 2010;116(13):2277–85.
128.
Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Personalized dendritic cell vaccines—recent breakthroughs and encouraging clinical results. Front Immunol. 2019;10:766.PubMedPubMedCentralCrossRef
129.
Roddie C, O’Reilly M, Dias Alves Pinto J, Vispute K, Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. 2019;21:327–40.PubMedCrossRef
130.
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off- the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–99.PubMedCrossRef
131.
Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing togenerate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255–66.PubMedCrossRef
132.
133.
134.
Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non–small cell lung cancer. Clin Cancer Res. 2008;14(16):5220–7.PubMedCrossRef
135.
Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol. 2008;108(1):106–11.PubMedCrossRef
Metadata
Title
Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review
Authors
Sandipan Dasgupta
Sakuntala Gayen
Tania Chakraborty
Naureen Afrose
Ranita Pal
Sutapa Mahata
Vilas Nasare
Souvik Roy
Publication date
01-05-2024
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02337-1

Other articles of this Issue 5/2024

Medical Oncology 5/2024 Go to the issue

Review Article

Dual function of activated PPARγ by ligands on tumor growth and immunotherapy

Original Paper

N-methyl-D-aspartate receptors and thymoquinone induce apoptosis and alteration in mitochondria in colorectal cancer cells

Original Paper

Immunomodulatory effects of Diospyros peregrina fruit preparation (DFP) in non-small cell lung cancer (NSCLC) by utilizing dendritic cell-mediated antigen presentation and T helper (TH) cell differentiation

Original Paper

Regulation of hippo signaling mediated apoptosis by Rauvolfia tetraphylla in triple-negative breast cancer

Original Paper

Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma

Review Article

The role of SWI/SNF complexes in digestive system neoplasms
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits